Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pCMV-Tag4A-MITF-M (wt) Citations (5)

Originally described in: Frequent mutations in the MITF pathway in melanoma.
Cronin JC, Wunderlich J, Loftus SK, Prickett TD, Wei X, Ridd K, Vemula S, Burrell AS, Agrawal NS, Lin JC, Banister CE, Buckhaults P, Rosenberg SA, Bastian BC, Pavan WJ, Samuels Y Pigment Cell Melanoma Res. 2009 Aug . 22(4):435-44.
PubMed Journal

Articles Citing pCMV-Tag4A-MITF-M (wt)

Articles
Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines. Noguchi K, Dalton AC, Howley BV, McCall BJ, Yoshida A, Diehl JA, Howe PH. PLoS One. 2017 May 17;12(5):e0177830. doi: 10.1371/journal.pone.0177830. eCollection 2017. PubMed
Interleukin-like EMT inducer (ILEI) promotes melanoma invasiveness and is transcriptionally up-regulated by upstream stimulatory factor-1 (USF-1). Noguchi K, Dincman TA, Dalton AC, Howley BV, McCall BJ, Mohanty BK, Howe PH. J Biol Chem. 2018 Jul 20;293(29):11401-11414. doi: 10.1074/jbc.RA118.003616. Epub 2018 Jun 5. PubMed
Inherited duplications of PPP2R3B predispose to nevi and melanoma via a C21orf91-driven proliferative phenotype. Polubothu S, Zecchin D, Al-Olabi L, Lionarons DA, Harland M, Horswell S, Thomas AC, Hunt L, Wlodarchak N, Aguilera P, Brand S, Bryant D, Carrera C, Chen H, Elgar G, Harwood CA, Howell M, Larue L, Loughlin S, MacDonald J, Malvehy J, Barberan SM, da Silva VM, Molina M, Morrogh D, Moulding D, Nsengimana J, Pittman A, Puig-Butille JA, Parmar K, Sebire NJ, Scherer S, Stadnik P, Stanier P, Tell G, Waelchli R, Zarrei M, Puig S, Bataille V, Xing Y, Healy E, Moore GE, Di WL, Newton-Bishop J, Downward J, Kinsler VA. Genet Med. 2021 Sep;23(9):1636-1647. doi: 10.1038/s41436-021-01204-y. Epub 2021 Jun 18. PubMed
Pharmacological attenuation of melanoma by tryptanthrin pertains to the suppression of MITF-M through MEK/ERK signaling axis. Shabna A, Antony J, Vijayakurup V, Saikia M, Liju VB, Retnakumari AP, Amrutha NA, Alex VV, Swetha M, Aiswarya SU, Jannet S, Unni US, Sundaram S, Sherin DR, Anto NP, Bava SV, Chittalakkottu S, Ran S, Anto RJ. Cell Mol Life Sci. 2022 Aug 10;79(9):478. doi: 10.1007/s00018-022-04476-y. PubMed
The C-terminal transactivation domain of MITF interacts promiscuously with co-activator CBP/p300. Brown AD, Lynch K, Langelaan DN. Sci Rep. 2023 Sep 26;13(1):16094. doi: 10.1038/s41598-023-43207-6. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.